Cargando…
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis
BACKGROUND: Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our understanding of timing of therapy when to commence therapy, which agent to choose and how...
Autores principales: | Simonini, Gabriele, Taddio, Andrea, Cattalini, Marco, Caputo, Roberto, de Libero, Cinzia, Parentin, Fulvio, Pagnini, Ilaria, Lepore, Loredana, Cimaz, Rolando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637103/ https://www.ncbi.nlm.nih.gov/pubmed/23587261 http://dx.doi.org/10.1186/1546-0096-11-16 |
Ejemplares similares
-
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic
por: Simonini, G, et al.
Publicado: (2011) -
Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008) -
Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2014) -
Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series
por: Taddio, Andrea, et al.
Publicado: (2011) -
A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
por: Rusche, Hendrik, et al.
Publicado: (2021)